Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Abstract Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting...

Full description

Bibliographic Details
Main Authors: Irati Macaya, Marta Roman, Connor Welch, Rodrigo Entrialgo-Cadierno, Marina Salmon, Alba Santos, Iker Feliu, Joanna Kovalski, Ines Lopez, Maria Rodriguez-Remirez, Sara Palomino-Echeverria, Shane M. Lonfgren, Macarena Ferrero, Silvia Calabuig, Iziar A. Ludwig, David Lara-Astiaso, Eloisa Jantus-Lewintre, Elizabeth Guruceaga, Shruthi Narayanan, Mariano Ponz-Sarvise, Antonio Pineda-Lucena, Fernando Lecanda, Davide Ruggero, Purvesh Khatri, Enrique Santamaria, Joaquin Fernandez-Irigoyen, Irene Ferrer, Luis Paz-Ares, Matthias Drosten, Mariano Barbacid, Ignacio Gil-Bazo, Silve Vicent
Format: Article
Language:English
Published: Nature Portfolio 2023-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-41828-z

Internet

https://doi.org/10.1038/s41467-023-41828-z

Similar Items